PD173074

Name: PD173074
Brand: Selleck Chemicals
SKU: S1264
Rating: 5 (96 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1264

96 publications

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Selleck's PD173074 has been cited by 96 publications

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(2):2002922

PubMed: 33511016 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3017

PubMed: 34021145 ( click the link to review the publication )

EMBO J, 2021, e107182

PubMed: 34086370 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4720

PubMed: 33946884 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-021-01061-1

PubMed: 33829354 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )
NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )

Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7037

PubMed: 31065021 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )
Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Dev Biol, 2018, 433(2):416-432

PubMed: 28760345 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(45):39185-39196

PubMed: 29045789 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Sci Rep, 2017, 7:41986

PubMed: 28155881 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )

J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )

Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317712592

PubMed: 28718374 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )
Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1613-21

PubMed: 25535896 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

Targets

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1581	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MW\JR\|UxRTBwMEGyNlUh\|ryP	NUP5Z\|ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KG-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH7ndZhKSzVyPUCuNFUyOjlizszN	NFfxVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MFM-223	NGPaO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnzaTWM2OD1yLkKxOVc3KM7:TR?=	M4nwc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EoL-1-cell	M2\6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlLaTWM2OD1yLkOyPVg1KM7:TR?=	M1zHSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
ECC10	NWrYRY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYnZbnpXUUN3ME2wMlM{QDl6IN88US=>	NIDoUGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
H-EMC-SS	M4XyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYHJR\|UxRTBwM{S3NVUh\|ryP	M1exVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
AN3-CA	M3nVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFqwZWdKSzVyPUCuOFAyOzNizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HuO-3N1	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2nkdmlEPTB;MD61OFY2OyEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
RT-112	NH3LbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIXofJRKSzVyPUCuOVQ4ODFizszN	NELQdGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NEC8	M1faVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1;4VWlEPTB;MD61OlI5QSEQvF2=	M33wRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-263MG	NWezbWhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX;JR\|UxRTBwN{GxOVkh\|ryP	NUnrWHh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW962	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF\KVWdKSzVyPUCuO\|g6QDhizszN	NVjtbohPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
BV-173	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2XJ[WlEPTB;MD64OFYzOyEQvF2=	NG\HdXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MFE-280	NHvXd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVXJR\|UxRTBwOEW4O\|Ih\|ryP	NVfFZ4g6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HuH-7	NHzT[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4LDXWlEPTB;MT6yOFQ3PCEQvF2=	M1TlRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
RS4-11	NEXafZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUHyPGdOUUN3ME2xMlM{QDh4IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DMS-114	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3nNW2lEPTB;MT6zOlc{PyEQvF2=	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MSTO-211H	M{XESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXTJR\|UxRTFwNEezO\|gh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DU-145	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmGwTWM2OD1zLkW4NlE4KM7:TR?=	NFrKcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A172	MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTFwN{CzOVUh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SBC-1	NHjQWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NW[yTWlnUUN3ME2yMlA6PCEQvF2=	Ml;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
H9	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHu1cGJKSzVyPUKuNVQ{ODZizszN	NEPuT249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-SNU-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NI\hNpFKSzVyPUKuNVg{QTRizszN	MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H720	NFrU[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWfUXndtUUN3ME2yMlIyOjh\|IN88US=>	Mn7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC2218	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTJwM{e5N\|kh\|ryP	NYP6WWt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
G-401	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml;DTWM2OD1{LkS3NVg6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MPP-89	NEPhfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYnJR\|UxRTJwNEizOlQh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
697	M3;IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3T5fmlEPTB;Mj62OVM{OSEQvF2=	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KARPAS-45	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1[1bmlEPTB;Mj63NFc1PyEQvF2=	M2fFc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MG-63	NVTkXYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3LnZWlEPTB;Mj65OFI3OiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	NIW0TVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnDU5czUUN3ME2zMlA{PDd{IN88US=>	Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
G-402	M{XRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkO1TWM2OD1\|LkGyO\|I4KM7:TR?=	Mn3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NKM-1	M4[wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHSyT4NKSzVyPUOuNVM2PjRizszN	MnHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
RH-18	NX7rWoV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3WwTGlEPTB;Mz6xPVU6QCEQvF2=	NGPtUJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1092	NXztendKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1j0T2lEPTB;Mz6xPVY6KM7:TR?=	MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
RPMI-8226	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3y4PGlEPTB;Mz6yN\|Q1PyEQvF2=	NFvGZmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
GAMG	NHvSdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV7JR\|UxRTNwNE[1O\|Yh\|ryP	NWmyVJl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HH	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXn1XHVSUUN3ME2zMlQ4Pjd4IN88US=>	M2rRPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
RO82-W-1	M135T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVq1blV5UUN3ME2zMlQ6QDV3IN88US=>	NUL3OlhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CCRF-CEM	M4raXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYTJR\|UxRTNwNUC0PFgh\|ryP	M2\mS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NBsusSR	NVX5Z5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2LxfGlEPTB;Mz62N\|k3QSEQvF2=	MnLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CHL-1	NWrmeYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn22TWM2OD1\|Lk[1O\|k6KM7:TR?=	M4q3b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LK-2	NVzvfoVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mnf4TWM2OD1\|Lk[3NVM{KM7:TR?=	NHWwU289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Hs-578-T	NUTZS4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWLJR\|UxRTNwNke4O\|Mh\|ryP	MnXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CTB-1	NUT5XYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX\3cFZDUUN3ME2zMlgxODVzIN88US=>	M3PQ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
ES5	NYXNV245T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVvJR\|UxRTNwOEO2N\|ch\|ryP	NUmxfYdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A204	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXz5SJFZUUN3ME2zMlkzODd3IN88US=>	NHTNU\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SW780	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH\GUYNKSzVyPUOuPVIzPDVizszN	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
EW-3	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHnobG5KSzVyPUOuPVg6OjNizszN	NVXIWZlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A704	NXX5[o1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVfJR\|UxRTRwMki3NlMh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-139	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{TCdWlEPTB;ND6zNVU{PCEQvF2=	NIPnVHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CAL-72	NWj4XIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXXJR\|UxRTRwNEG3OFYh\|ryP	NITWR5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
D-336MG	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWPJR\|UxRTRwNE[4NVch\|ryP	NYDWO2F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LAMA-84	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3myTGlEPTB;ND61N\|MyKM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GI-ME-N	M1nBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7aWI1KSzVyPUSuOVQ5OSEQvF2=	NVi5RZljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KM-H2	NH7uWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{DLTGlEPTB;ND61OVIzOiEQvF2=	NGfucFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H209	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3fnNmlEPTB;ND61PFI5OyEQvF2=	NYLEVI45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
IGROV-1	NEi0cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUWzcZREUUN3ME20Mlg4OTZ6IN88US=>	NIHiXpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
L-363	M1fEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGPZ[WhKSzVyPUSuPVY3PjVizszN	MlmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NFPHcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHnJdG9KSzVyPUWuNlQxPiEQvF2=	M1;jOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HuO9	M4XXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnLnTWM2OD13LkO4PFQ{KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NOS-1	NFywUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3\yUmlEPTB;NT63NlkzPyEQvF2=	NGnzR4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1770	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIDVT3NKSzVyPUWuPVUxOzJizszN	MmPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SF126	M4D6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnj2TWM2OD14LkKxOFA3KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ML-2	M1Tjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXjJR\|UxRTZwMkS5O\|ch\|ryP	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CHP-134	NG\DboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3;UTmlEPTB;Nj6yOVE5OiEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1355	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MonPTWM2OD14LkSxO\|M{KM7:TR?=	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
TE-12	NVvRfFVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{PuSWlEPTB;Nj63NlY4OSEQvF2=	NH3Kcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A4-Fuk	NWjHeGh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mo\aTWM2OD14LkezNVQzKM7:TR?=	NHL1PI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MV-4-11	NGXySVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmC5TWM2OD14Lke2OlI3KM7:TR?=	M4WyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-UT-1	NFfJTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3q5OWlEPTB;Nj65NVc5PCEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4iyZmlEPTB;Nz6wO\|c3PCEQvF2=	NHvHO249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ME-180	M3HHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGHOe4FKSzVyPUeuNVA1ODRizszN	NFf1bGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SK-MEL-28	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4jDVWlEPTB;Nz6zO\|gyQSEQvF2=	M2rXO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HAL-01	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYKybFdoUUN3ME23MlQ5OzRzIN88US=>	NYL5VlIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ES8	M1LTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Moi3TWM2OD15Lk[5OlI3KM7:TR?=	NXXGW3hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DB	NUnES2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWjpSVFDUUN3ME24MlEyPTB2IN88US=>	MonFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	M1;XT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoW2TWM2OD16LkS4NVQ6KM7:TR?=	M{D2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
COR-L88	NX;nXGtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3fkdWlEPTB;OD61NFk5OSEQvF2=	NVXTRnVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	NUW2colIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF;vO2VKSzVyPUiuOVIzOTJizszN	M2TV[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H520	NYDsOJZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2\4S2lEPTB;OD62NlE2PyEQvF2=	Mn3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SW954	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVHHRmNkUUN3ME24MlY6Pzh4IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TE-6	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlvPTWM2OD16Lke1NVQ{KM7:TR?=	NVvlZ41kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
D-283MED	NHfYfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHzyO3RKSzVyPUmuNFY2OzRizszN	M1i5clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DBTRG-05MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF\4RmFKSzVyPUmuNFk3ODdizszN	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H446	NVjuV3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{TFXWlEPTB;OT6yPVUzPiEQvF2=	M2\2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HOS	M3LKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mm[0TWM2OD17LkO1NVM1KM7:TR?=	NVHDSIt4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ES4	NILSd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUDzeoZFUUN3ME25MlUxPTl3IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EW-13	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mnn4TWM2OD17Lki5NFU2KM7:TR?=	NVHMUmJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
IST-MES1	M{XRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYjJR\|UxRTlwOUS1N\|Qh\|ryP	M1[ySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CAS-1	NWnZdINmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTlwOUe2OVkh\|ryP	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
EM-2	NVy5emE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXkXm5nUUN3ME2xNE4yOzl\|IN88US=>	M3XNeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW948	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGrsSXJKSzVyPUGwMlE5QDJizszN	NV7Uco9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
OAW-42	NGfuS\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVPZUmF5UUN3ME2xNE42OjZ5IN88US=>	NX\JfpoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
BE-13	NHjHcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2DxUWlEPTB;MUCuOlU4PiEQvF2=	MnThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KU812	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWHJR\|UxRTFyLkezPVEh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-30	NH31d5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTFyLki5NFEh\|ryP	MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A2780	Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkjyTWM2OD1zMT6wN\|A5KM7:TR?=	NFy4TXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TGBC24TKB	M1jxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mk\uTWM2OD1zMT6wO\|M4KM7:TR?=	NGSwfIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
GOTO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTFzLkKwPFQh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H526	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3Wwc2lEPTB;MUGuN\|g{PyEQvF2=	M3va[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
BHT-101	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1fGd2lEPTB;MUGuOFQ2PiEQvF2=	NITabWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1155	NXrxOZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH7zb2VKSzVyPUGxMlQ6PDdizszN	M13yVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MCF7	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIjxfYpKSzVyPUGxMlYyPjdizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MKN45	NHPW[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX7JR\|UxRTFzLke5PVMh\|ryP	M3SzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MOLT-16	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX[4Xm5rUUN3ME2xNU46Pjl{IN88US=>	M1LHblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
YH-13	M3nyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTF{LkCzOFYh\|ryP	M1GxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	NYHQdJRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1jOcmlEPTB;MUKuN\|g1PSEQvF2=	NYj3SHBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GR-ST	NWnTXIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUnUV\|ZDUUN3ME2xNk42Ojl3IN88US=>	NHzPNoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CAKI-1	NXq5bnFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2LGbGlEPTB;MUKuO\|kyKM7:TR?=	NWqzN\|dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LXF-289	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVrJR\|UxRTF\|LkC4N\|Uh\|ryP	NIrwZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MHH-PREB-1	M1rzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M33CWWlEPTB;MUOuNlcxPCEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EW-16	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlrpTWM2OD1zMz6zNVg4KM7:TR?=	MkD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H82	Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1[zPWlEPTB;MUOuOFE6PSEQvF2=	NVvGfoZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MMAC-SF	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWOzR\|R{UUN3ME2xN{41PTR5IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
COLO-684	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVzJR\|UxRTF\|LkWzNVgh\|ryP	NEHUb2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
QIMR-WIL	M3LVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIf2bWJKSzVyPUGzMlgyODlizszN	MlH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NB69	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2joeWlEPTB;MUOuPVg3QCEQvF2=	NWfqOmNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H2291	M{CzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fXVmlEPTB;MUSuOFQ2OyEQvF2=	NGDZe4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MKN7	M17PVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH7MemZKSzVyPUG0MlY3PzZizszN	MkLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HDLM-2	M1XCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGLwNFBKSzVyPUG1MlEzQDZizszN	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A253	NXHGOZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmnuTWM2OD1zNT6zPFY6KM7:TR?=	NXSwdnNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-LU-1	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml2yTWM2OD1zNT65NFk1KM7:TR?=	NIXvVpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MEG-01	NWPrclh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTUWJpRUUN3ME2xOU46OTB5IN88US=>	NGTXXow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SK-N-DZ	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmDXTWM2OD1zNT65N\|c3KM7:TR?=	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
H4	NXW0dZZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYjJR\|UxRTF4LkC4PEDPxE1?	M{LrNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LU-65	NHzuc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGG3cJlKSzVyPUG2MlM{QDRizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1048	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXzJR\|UxRTF4LkWxOlUh\|ryP	M1;lVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LCLC-97TM1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmXPTWM2OD1zNj61PFg6KM7:TR?=	NHTWUFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CAL-120	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEjHU2RKSzVyPUG2Mlk5PzlizszN	M3LTWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LU-134-A	NHfSWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTF5LkOzPVEh\|ryP	NFT4cos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SK-MEL-1	NXXQOlhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2izR2lEPTB;MUeuO\|EzPyEQvF2=	NWHz[5hORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H69	NF;FSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnzQTWM2OD1zNz65N\|A4KM7:TR?=	MnPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MC116	NIHBSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH65NGNKSzVyPUG3Mlk4PSEQvF2=	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
UMC-11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUXJR\|UxRTF6LkG3PFgh\|ryP	M3;Ge\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCC1395	NH\FSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkOzTWM2OD1zOD60N\|AyKM7:TR?=	NHTJblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
no-10	NHXzTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEfodoRKSzVyPUG4MlY{QDhizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NY	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX;XbYlsUUN3ME2xPU4xQDB7IN88US=>	Ml7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
OS-RC-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFHX[pJKSzVyPUG5MlEzPTJizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
D-423MG	NFn6WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoXOTWM2OD1zOT6zPVUzKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LC-2-ad	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mnn1TWM2OD1zOT63OlEzKM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DU-4475	NYnCOZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{LxR2lEPTB;MUmuPFg2OiEQvF2=	NX7QTVRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
YKG-1	NFTafIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGS5bmdKSzVyPUG5Mlk3OiEQvF2=	MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC1569	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPBTlJiUUN3ME2yNE4zPjJ2IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TYK-nu	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1:wPGlEPTB;MkCuNlg1PyEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DEL	M4jyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWfJR\|UxRTJyLkm4NFgh\|ryP	M1uwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MHH-ES-1	NVro[2MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXfJR\|UxRTJzLkO1PVch\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KARPAS-299	NGrENYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWHJR\|UxRTJzLkWyPUDPxE1?	NHv6fZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CTV-1	M2PJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV\JR\|UxRTJzLk[xO\|Ih\|ryP	MmXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H2452	NFmzc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTJ{Lk[2O\|ch\|ryP	M2qwXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-566MG	NX[xW49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVnJR\|UxRTJ{Lke2NFEh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EFO-27	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH\kVGVKSzVyPUKzMlA3PTFizszN	M2L1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H596	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXHJR\|UxRTJ\|Lki1Nlch\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KS-1	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4PYemlEPTB;MkSuNlc2QSEQvF2=	M{PjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
8305C	NIXKVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTJ2LkSwOFUh\|ryP	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A427	M2eyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NELnOHhKSzVyPUK1MlA{OjNizszN	MkHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
COLO-800	NHvZTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGr3ZnhKSzVyPUK1MlExPjFizszN	NEfZdGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SJRH30	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXrsUpp4UUN3ME2yOU4{QTB6IN88US=>	M1e0R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MEL-HO	NF7ST4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUHKZnBEUUN3ME2yOU41OzF7IN88US=>	NVrpRnNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
FTC-133	NHfxNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFjY[GhKSzVyPUK1MlgyQDZizszN	M4LMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SF295	NGnPUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTJ4LkK5OkDPxE1?	M3zzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW1710	M4XOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1LFRWlEPTB;Mk[uOFEzOyEQvF2=	NHfqUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EFM-19	NV3jT\|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnvDTWM2OD1{Nj64NVQ2KM7:TR?=	M2q1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NB10	NWPKPIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoL5TWM2OD1{OD6yNlk4KM7:TR?=	NUi4ZpVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
TK10	M{S4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFvpcHJKSzVyPUK4MlI{QTlizszN	M{\hPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-502MG	NWrzdoZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYHOd5dOUUN3ME2yPE41KM7:TR?=	M1vse\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EW-18	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWDJR\|UxRTJ6LkSzPFYh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	M{TwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4e4dGlEPTB;MkiuPVQyKM7:TR?=	NVr3cnNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
Ca9-22	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGX0bnVKSzVyPUK5MlQ2PTdizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KYSE-70	M4PzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUPJR\|UxRTJ7LkW3PFYh\|ryP	NIC0Tmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A101D	NVXhfVduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVH0N5F6UUN3ME2yPU43PDd{IN88US=>	NH\XcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
WM-115	M3jwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVfZWlZLUUN3ME2yPU44PjB5IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HCC2157	M1;XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFr2fJJKSzVyPUK5Mlg5ODdizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TE-9	M{niWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NW\KWmZYUUN3ME2yPU45QDZ3IN88US=>	M4nEV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
K-562	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFnGOotKSzVyPUOwMlA6OzNizszN	Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SN12C	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MofPTWM2OD1\|MD6xOFI3KM7:TR?=	NHv4R449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ESS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3[5R2lEPTB;M{CuOFc2QSEQvF2=	MojjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
K5	NEjZ[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1G5TWlEPTB;M{CuO\|Y1KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
J82	NIHoU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmjxTWM2OD1\|MT6wPFk4KM7:TR?=	MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HOP-92	M2jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWntXpFmUUN3ME2zNU4yOTFzIN88US=>	NGDHclc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H2228	M1jZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnn6TWM2OD1\|MT6zNlk3KM7:TR?=	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
OCI-AML2	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2LjUmlEPTB;M{GuN\|YyKM7:TR?=	NYeydldqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	M3HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXXLSIV2UUN3ME2zNU45OTN5IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A3-KAW	NWq4dpZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTNzLkmyOFMh\|ryP	NFnjZlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LCLC-103H	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH;xdlZKSzVyPUOyMlAyPzFizszN	MnThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KY821	NWqyXZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE\PUWNKSzVyPUOyMlY5QDRizszN	M1;WelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
JVM-2	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTN{LkmwO\|kh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
Mo-T	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3mwd2lEPTB;M{OuNVAxPSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
IA-LM	NHnWVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NULte29CUUN3ME2zN{4zPzVizszN	NUTaOXVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
C8166	NWHZZVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlH5TWM2OD1\|Mz6zNVkzKM7:TR?=	NF;TbpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TCCSUP	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlXwTWM2OD1\|Mz60N\|A4KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
JEG-3	M1nDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoLtTWM2OD1\|Mz60O\|Y5KM7:TR?=	NIHZfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTN\|LkW1OVEh\|ryP	MoPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H1304	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MorhTWM2OD1\|Mz61O\|I2KM7:TR?=	M1Gzd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	M3\ye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFLSd41KSzVyPUO0MlA{OzVizszN	Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-453	NEC3OW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTN2Lk[zPVUh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KYSE-520	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\DVFY{UUN3ME2zOE44OThzIN88US=>	NUPtO3BqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW900	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnrGTWM2OD1\|ND64NVE2KM7:TR?=	M2Sye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCC2998	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{CwWmlEPTB;M{WuNVUzQSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A2058	NF7wdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3XGNGlEPTB;M{WuOlA3OSEQvF2=	NXfqbZJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
OVCAR-3	NIPrPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXHGfIl3UUN3ME2zOk4zODR3IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MOLT-4	M1qwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIjzXFBKSzVyPUO2MlIzQTRizszN	Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CAPAN-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mnf2TWM2OD1\|Nj60Olk6KM7:TR?=	NXLzdpRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SCC-9	M3f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWX2SHdjUUN3ME2zO{41ODJ5IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SF268	M2DmVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVvGSYdTUUN3ME2zPE4{PDN\|IN88US=>	NVvHbGdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HGC-27	NXO4fGE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUnJR\|UxRTN6LkO3NVEh\|ryP	M2jzOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DOHH-2	M{\JWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NETlcoNKSzVyPUO4MlcyPThizszN	NETHW2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KE-37	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MknBTWM2OD1\|OD65PFI5KM7:TR?=	M3jsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MOLT-13	NGjTVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2jt[GlEPTB;M{muNlUxOiEQvF2=	NEfOVHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFH2dVNKSzVyPUO5MlM5PSEQvF2=	NEX0R5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SK-OV-3	MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUP3PWRZUUN3ME2zPU46PjR\|IN88US=>	M4PMb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SNU-449	M{LMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX71UZY1UUN3ME20NE4xPzZ2IN88US=>	MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KYSE-510	NIrHZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWHRblMzUUN3ME20NE4yOjl3IN88US=>	NV7KSIVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HL-60	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGrKN\|JKSzVyPUSwMlk4QDNizszN	MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DJM-1	M2T4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7tcHRKSzVyPUSwMlk4QTlizszN	M2ryPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
TGBC11TKB	NY\sRnQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWf3fW9xUUN3ME20NU4xQTJ4IN88US=>	M1rOXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
U-2-OS	NEOzWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{fnNmlEPTB;NEKuNlY1OSEQvF2=	NXHYOppkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H2030	M3Pjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF;DbpJKSzVyPUSyMlQ{PjhizszN	M1jwdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LU-135	NIDF[\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYLjTpM4UUN3ME20Nk42PDR5IN88US=>	NGXDepo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ZR-75-30	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVHJR\|UxRTR\|LkC0PVMh\|ryP	Mn;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
GT3TKB	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF7Xd2hKSzVyPUSzMlI3PzlizszN	NEfl[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RPMI-2650	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MorpTWM2OD12Mz63PFE3KM7:TR?=	NHXvZ4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SAS	M2rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlqxTWM2OD12Mz65OVM1KM7:TR?=	MkGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-231	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUfJR\|UxRTR\|Lkm2NFkh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
JVM-3	NXv3TGVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoTyTWM2OD12ND6wOVM{KM7:TR?=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	NX;HO5VsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTR2LkW2N\|Mh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SNB75	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFS0Z5JKSzVyPUS0MlYyODVizszN	NGPqSVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H441	NYPydVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHqyWoxKSzVyPUS0Mlk{OjhizszN	NUWzfZYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCT-116	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUDqOIdRUUN3ME20OE46QDZ6IN88US=>	M{LpW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H226	NVr5PVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nZTmlEPTB;NEWuOlM3QCEQvF2=	MmO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CAL-33	NEj5NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTR3LkmyNVch\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1437	NY\CTI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF2y[IZKSzVyPUS2MlMzOSEQvF2=	NEjhdXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HCC1187	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1rYNGlEPTB;NE[uOFI2PSEQvF2=	NH\ydm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NUGC-3	NWfCXYJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4H0UmlEPTB;NE[uOVcxQSEQvF2=	MnHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
T98G	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUXJR\|UxRTR5LkW0O{DPxE1?	M3Tve\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OVCAR-8	NVG5b292T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1HySWlEPTB;NEeuOlg{KM7:TR?=	M{PER\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LB2241-RCC	NXX4VmRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MojTTWM2OD12Nz63Nlch\|ryP	MnfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H358	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXizfnptUUN3ME20PE4yOTV{IN88US=>	MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
PANC-08-13	NY\X[5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUfQZ\|R1UUN3ME20PE4yQDV\|IN88US=>	Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KP-N-YN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mkj1TWM2OD12OD6yNVAzKM7:TR?=	M4nRWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H1755	NULuTYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2e4OGlEPTB;NEiuNlczPiEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-N87	NF25VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3rFdWlEPTB;NEiuNlk6OSEQvF2=	NUDLPYU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SUM52	NUXYfXNKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXTFR2dsPSCmYYnz	NW\LW5RKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGS2ZTOi2jbYDsbYZq\WRiU2XNOVIh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFEzOyEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{MUG1Okc,Ojh3MkGxOVY9N2F-
RT112	M2P4S2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4fCN\|czKGi{cx?=	M1HPVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmSxNVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFE2KM7:TT6=	M2juNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUm5O\|QzLz5{N{W5PVc1OjxxYU6=
insect cells	MWPGeY5kfGmxbjDhd5NigQ>?		NYXpfIxIOTBibXnudy=>	MUXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIF\HSnIyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhY2ejbX3hMVMzWF2DVGCgZYZ1\XJiMUCgcYlveyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKGKjc3XkJJJi\GmxYXP0bZZmKG[rbITldkBjcW6maX7nJIF{e2G7LDDJR\|UxKD1iMD6wNlE2KM7:TT6=	NF;0XIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxOFM3Oid-Mke5NVQ{PjJ:L3G+
SW780	NEn4cXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF7ne4Q2KGSjeYO=	M3fS[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRlfGVlMu[W2ybHnmbYVlKFOZN{iwJINmdGy\|IHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkC4OFMh\|ryPLh?=	NFnRfXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyNVE2Pid-Mki1NlEyPTZ:L3G+
NIH/ 3T3	Mn\VSpVv[3Srb36gZZN{[Xl?		NHq4eY02KG2rboO=	NWjt[ncyUW6qaXLpeIlwdiCxZjDWSWdHWjJiKIXub45wf25ib4Lp[4lvMSCxdnXy[ZhxemW\|c3XkJIlvKG2xdYPlJG5KUC9iM2SzJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIZwdGyxd3XkJIJ6KHO2aX31cIF1cW:wIIfpeIghXkWJRjDmc5IhPSCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7nJIFv[Wy7c3nzMEBKSzVyIE2gNE4yKM7:TT6=	M3PnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{K2N\|M6Lz5{N{OyOlM{QTxxYU6=
NCI-H520	NIjaS5dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIf2OYk4KGSjeYO=	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[JRmKxMYFueGyrZnnl[EBPS0lvSEWyNEBk\WyuczDh[pRmeiB5IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6yPFEh\|ryPLh?=	NXzOZXo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlEyPTZpPkK4OVIyOTV4PD;hQi=>
HUVEC	MX7GeY5kfGmxbjDhd5NigQ>?	M33zPFExKG6P	MUCxOEBpenN?	NWXTSIZEUW6qaXLpeIlwdiCxZjDGS2ZTNW2nZHnheIVlKGGwZ3nv[4Vv\XOrczDpckBpfW2jbjDIWXZGSyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDjZZBqdGyjcomgeJVj\SC\|cILveZRqdmdiYYSgNVAhdk1iYX\0[ZIhOTRiaILz	NIT3VIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS3OFM5Pyd-MU[0O\|Q{QDd:L3G+
HUVEC	NFfm[oxHfW6ldHnvckBie3OjeR?=	MlHmNVAxKG6P	NFHTclUyPCCqcoO=	M3H5V2lvcGmkaYTpc44hd2ZiRlfGVk1u\WSrYYTl[EBidmerb3flcoV{cXNiaX6gbJVu[W5iSGXWSWMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3HwbYxt[XK7IIT1ZoUhe3C{b4X0bY5oKGG2IEGwNEBvVSCjZoTldkAyPCCqcoO=	NYjte\|h6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0O\|Q{QDdpPkG2OFc1Ozh5PD;hQi=>
SJ-GBM2	NGXEXY5yUFSVIHHzd4F6			Mmq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NVXJT5ZmeUiWUzDhd5NigQ>?			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M2PXXZFJXFNiYYPzZZk>			NUDEVVlFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NWH0TY4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NEPvWHNyUFSVIHHzd4F6			MmfwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	Mn3qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MX3xTHRUKGG\|c3H5			M{\ydJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MnPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MmCzdWhVWyCjc4PhfS=>			MmrEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NYPySWJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M4[2V5FJXFNiYYPzZZk>			MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NEHwTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	M4TsTZFJXFNiYYPzZZk>			NHH6UY1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NUfqVoFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M1vsRpFJXFNiYYPzZZk>			MoLMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NIrLSG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MnnadWhVWyCjc4PhfS=>			MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NV7xfnV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
fibroblast cells	MUTxTHRUKGG\|c3H5			MoD0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKGOxboTyc4whUGhid3ns[EB1gXCnIH\pZpJw[myjc4SgZ4VtdHN?	M1HXTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	Mo[ydWhVWyCjc4PhfS=>			NXH0fFR5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

In vivo

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-³²P]ATP (5 μM ATP containing 0.4 μCi of [γ-³²P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [³²P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:^[4]	- Collapse Cell lines: KMS11 and KMS18 Concentrations: Dissolved in DMSO, final concentrations ~100 nM Incubation Time: 48 hours Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Swiss Webster mice with induced corneal angiogenesis Dosages: ~2 mg/kg/day Administration: Administered intraperitoneally (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD173074 SDF

Molecular Weight	523.67
Formula	C₂₈H₄₁N₇O₃
CAS No.	219580-11-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of PD173074(S1264) in vivo?
Answer:
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Pan FGFR Inhibitor

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
Most Potent FGFR Inhibitor

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Related FGFR Products

CH5183284 (Debio-1347) ^New

CH5183284 (Debio-1347, FF284) is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Infigratinib (BGJ398)

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
AZD4547

AZD4547 (ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074